Loading...

LQDA - Liquidia Corporation

Analyst Reiterated Signal for 01-05-2024
Analyst Reiterated/Price Target Changed: LQDA rating Buy by Needham
Price Target: $18>>28



Stock Signal Information


Signal

Analyst Reiterated Stock
Report Date: 01-05-2024
Symbol: LQDA - Liquidia Corporation
Sector: Healthcare
Industry: Biotechnology
Analyst Reiterated/Price Target Changed: LQDA rating Buy by Needham
Price Target: $18>>28

  LQDA Technical Chart

Company Contact

Liquidia Corporation (LQDA)
419 Davis Dr Ste 100
Durham, NORTH CAROLINA 27560
Phone: 19193284400
Website: https://www.liquidia.com
CEO: Mr. Neal Fowler


Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include LIQ861, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension; and LIQ865, a sustained-release formulation of bupivacaine for the treatment of local post-operative pain. The company also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.